We are live on ! Find out more
EGRX

Eagle Pharmaceuticals, Inc.
EGRX

Delisted

EGRX was delisted on the 2nd of October, 2024.

Back to rankings

149 hedge funds and large institutions have $1.31B invested in Eagle Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 48 increasing their positions, 46 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

94% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 16

12% more call options, than puts

Call options by funds: $20.7M | Put options by funds: $18.4M

12% more capital invested

Capital invested by funds: $1.17B → $1.31B (+$136M)

9% more funds holding

Funds holding: 137 → 149 (+12)

4% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 46

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

Holders
149
Holders Change
+12
Holders Change %
+8.76%
% of All Funds
3.72%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.15%
New
31
Increased
48
Reduced
46
Closed
16
Calls
$20.7M
Puts
$18.4M
Net Calls
+$2.23M
Net Calls Change
-$8.96M

Top Buyers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
+$12.6M
2
CM
Castleark Management
Illinois
+$8.46M
3
State Street
State Street
Massachusetts
+$6.87M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.68M
5
BFA
BlackRock Fund Advisors
California
+$6.06M

Top Sellers

Rank Fund Capital Flow
1
PAI
ProQuest Associates IV
Florida
-$31.3M
2
O
OrbiMed
New York
-$26.5M
3
PC
PointState Capital
New York
-$21.3M
4
JCI
Jet Capital Investors
New York
-$9.44M
5
Morgan Stanley
Morgan Stanley
New York
-$8.74M
Name Holding Trade Value Shares
Change 		Change in
Stake
TI
76
Turner Investments
Pennsylvania
$1.07M +$981K +13,500 New
Legal & General Group
77
Legal & General Group
United Kingdom
$1.06M +$463K +6,368 +92%
GC
78
Globeflex Capital
California
$1.01M +$923K +12,700 New
RhumbLine Advisers
79
RhumbLine Advisers
Massachusetts
$987K +$52.8K +727 +6%
ProShare Advisors
80
ProShare Advisors
Maryland
$936K +$65.5K +902 +8%
T. Rowe Price Associates
81
T. Rowe Price Associates
Maryland
$886K +$128K +1,764 +19%
Canada Life
82
Canada Life
Manitoba, Canada
$814K -$38.5K -530 -5%
New York State Teachers Retirement System (NYSTRS)
83
New York State Teachers Retirement System (NYSTRS)
New York
$790K +$14.5K +200 +2%
EGM
84
Engineers Gate Manager
New York
$767K +$702K +9,665 New
DekaBank Deutsche Girozentrale
85
DekaBank Deutsche Girozentrale
Germany
$756K +$54.5K +750 +8%
AL
86
Airain Ltd
Guernsey
$721K +$660K +9,083 New
LCG
87
Lisanti Capital Growth
New York
$714K +$653K +8,995 New
Dimensional Fund Advisors
88
Dimensional Fund Advisors
Texas
$590K +$540K +7,437 New
Comerica Bank
89
Comerica Bank
Texas
$585K +$30.1K +415 +5%
AWCI
90
Alpine Woods Capital Investors
New York
$555K – – –
SG Americas Securities
91
SG Americas Securities
New York
$536K +$319K +4,385 +185%
State of Tennessee, Department of Treasury
92
State of Tennessee, Department of Treasury
Tennessee
$504K – – –
AIG
93
American International Group
New York
$502K -$7.55K -104 -2%
MLICM
94
Metropolitan Life Insurance Company (MetLife)
New York
$495K – – –
Manulife (Manufacturers Life Insurance)
95
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$494K -$13.4K -185 -3%
Fisher Asset Management
96
Fisher Asset Management
Washington
$459K -$274K -3,770 -39%
TPSF
97
Texas Permanent School Fund
Texas
$456K -$24.2K -333 -5%
WPC
98
White Pine Capital
Minnesota
$450K – – –
Public Sector Pension Investment Board (PSP Investments)
99
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$444K – – –
SEI Investments
100
SEI Investments
Pennsylvania
$431K +$394K +5,430 New
2 3
4
5 6

EGRX Hedge Fund Activity: Q4 2016 in Review

149 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q4 2016, worth a combined $1.31B — up 12% from $1.17B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new EGRX positions and 16 closed out — a net gain of 15 holders — while 48 added to existing stakes and 46 trimmed.

The largest buyer was Victory Capital Management, adding an estimated $12.6M. The largest seller was ProQuest Associates IV, cutting an estimated $31.3M.

  • 149 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q4 2016, up from 137 in Q3 2016.
  • Funds reported $1.31B of Eagle Pharmaceuticals, Inc. stock for Q4 2016, up 12% quarter-over-quarter.
  • 31 funds opened new Eagle Pharmaceuticals, Inc. positions in Q4 2016 and 16 closed out, a net change of +15 holders.
  • The largest Eagle Pharmaceuticals, Inc. buyer in Q4 2016 was Victory Capital Management, an estimated $12.6M added.
  • The largest Eagle Pharmaceuticals, Inc. seller in Q4 2016 was ProQuest Associates IV, an estimated $31.3M sold.

Based on aggregated 13F filings for Q4 2016.